Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (23434)	7/22/1998 6:38:00 PM
From: RevMikeB	Read Replies (1) \| Respond to of 32384

I agree that Targretin shows a lot of potential. I think that this is the only real money maker that Lignad has coming out over the next couple of years. It is like a wonder drug, which might be used to combat many diseases. If this drug showed any big problems, I would dump LGND in a heart beat and revisit the company a few years down the line, but I anticipate good things right now from Targretin. I think getting the drugs approved by fast track for smaller markets is smart and the best option for LGND and shareholders. There is a downside though: when drugs are approved, the news gets to everyone more so than at any other time for biotechs. If it's for small markets, the street might shrug their shoulders at LGND and look at other companies. Off-label use is harder to predict since Doctors might not know about using Targretin as other treatments or they might be less inclined to do it without FDA approval. Just MHO. RevMikeB